# Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials.

- **DOI:** [10.3389/fnut.2025.1494351](https://doi.org/10.3389/fnut.2025.1494351)
- **Rating:** Sound (3.0 out of 5)
- **Verdict:** A clinically useful synthesis showing curcumin benefits ulcerative colitis but not Crohn's disease, constrained by unexplored extreme heterogeneity and missing certainty-of-evidence assessment.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-06-15
- **Evaluation page:** https://www.nabu.science/paper/10.3389%2Ffnut.2025.1494351

## Strengths

- **Clinically useful UC versus CD differentiation** The review separates ulcerative colitis from Crohn's disease rather than pooling them, reporting a positive UC signal and a null CD result. This is clinically meaningful given the distinct pathophysiology of the two conditions and is reported without spin.
  - Dimension: contribution
  - Location: Results, UC and CD efficacy subsections; Conclusion
- **Sound systematic-review process and reporting** Five databases plus Google Scholar were searched with snowball screening, four independent researchers screened and extracted with consensus resolution, and pooled risk ratios with 95% confidence intervals and heterogeneity statistics are reported throughout.
  - Dimension: methodological rigour
  - Location: Methods, Study selection and Data extraction; Results, Figures 3-4
- **Appropriately hedged, well-structured presentation** The paper follows a logical structure and uses cautious language ('might be more beneficial', 'further research is warranted'), presenting both positive and null findings without overstatement.
  - Dimension: reporting
  - Location: Abstract; Conclusion

## Limitations

- **Extreme heterogeneity left unexplored** Clinical remission in UC carries I²=88% heterogeneity, yet no subgroup or sensitivity analysis examines obvious sources such as formulation, dose (0.1-10 g), or disease severity. This weakens interpretability of the pooled estimate.
  - Dimension: methodological rigour
  - Location: Methods, Statistical analysis; Results, UC efficacy subsection
- **No publication bias or certainty assessment** No funnel plot, Egger's test, or other publication bias assessment is reported, and no GRADE certainty-of-evidence rating is provided, both standard expectations for a contemporary clinical systematic review. Readers cannot judge whether the positive UC findings are robust to small-study effects.
  - Dimension: positioning
  - Location: Methods and Results (assessment absent)
- **Selective emphasis across ITT and PP** Endoscopic remission is significant in per-protocol analysis (RR 2.11, p=0.007) but not in intention-to-treat (RR 3.81, p=0.06), and the framing leads with the significant analysis without flagging the discordance as a limitation.
  - Dimension: methodological rigour
  - Location: Results, Clinical efficacy of curcumin versus placebo in UC

## Reliability checks

Caveats (3 of 4 checks).

- **Internal coherence:** Noted. Core numerical reporting is internally consistent (13 RCTs, record counts, effect estimates with CIs), but interpretive framing in the Abstract and Discussion emphasizes significant outcomes while non-significant ITT/PP results for the same endpoints receive less prominence, and very high heterogeneity is reported without analytical exploration.
- **Research conduct:** Noted. Preregistration on PROSPERO and an appropriate ethics statement for a review of published data are declared, but no conflict-of-interest declaration is visible, the data availability statement is generic with no repository, and protocol timing relative to search/screening cannot be confirmed from the text.
- **Reference integrity:** Pending

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
